Context Therapeutics announces preclinical data on CTIM-76

Context Therapeutics announced encouraging preclinical data regarding the Company’s preclinical asset, CTIM-76, a Claudin 6 x CD3 T-cell engaging bispecific antibody. Findings from Context’s research team, in conjunction with development partner Integral Molecular, illustrate the potential of CTIM-76 to treat CLDN6-positive tumors. Notably: CTIM-76 was shown to have high potency and target selectivity in both binding and cytotoxicity assays. In in vivo xenograft experiments, CTIM-76 induced dose-proportional tumor regressions and was well tolerated. In IND-enabling toxicology studies, CTIM-76 was well tolerated, and a potential first-in-human dose was identified. Clones of clinical-stage molecules TORL-1-23 and AMG-794 were generated for benchmarking purposes. In comparison studies, TORL-1-23 activity appeared dependent upon high CLDN6 expression whereas CTIM-76 activity was retained across a range of cell lines expressing with low through high CLDN6. Additionally, CTIM-76 demonstrated ten-fold higher potency than AMG-794 in in vitro cytotoxicity and cytokine activation.